Welcome to the Horizon 2020 atherosclerosis research program website
On May 26 until May 29 2019 the open-end congres of REPROGRAM will be held at the 87th European Atherosclerosis Society in Maastricht. You can sign in with the following link: https://eas2019.com/the-congress/satellite-symposia/immunometabolism/ Untitled
Prof. Niels RIksen (RadboudUmc, Nijmegen) teamed up with dr. Andreas Schlitzer (University of Bonn, Germany) and dr. Hafid Ait-Oufella (St-Antoine Hospital and Inserm , France). They prepared a successful transnational ERA-CVD research application entitled MEMORY. Due to the worldwide adoption of Western lifestyle, the prevalence of obesity increases exponentially. Obesity is an important risk factor for
On January 21 2019, the Governing Council meeting was held at Schiphol Amsterdam airport for the REPROGRAM project. After a warm welcome by Prof. Dr. Erik Stroes (Project Coordinator) the meeting started immediately with presentations of Prof. dr. Niels Riksen (RadboudUMC), Prof. dr. Erik Stroes (AMC), Prof dr.Borge Nordestgaard (Copenhagen University Hospital) and Prof. dr.
The AMC groups of Prof. Stroes and Prof. de Winther published recently a review article on epigenetic therapeutics for atherosclerosis in the Atherosclerosis journal. Common epigenetic modifications such as DNA methylation and histone post-translational modifications are in the spotlight of epigenetic therapeutics and are show promise for the treatment of many diseases including cancer, diabetes,
Lipoprotein(a) (Lp(a)) elevation is a causal risk factor for cardiovascular disease. It has however been suggested that elevated Lp(a) causes cardiovascular disease mainly in individuals with high low-density lipoprotein cholesterol (LDL-C) levels. Therefore it was hypothesized that the risk associated with high Lp(a) levels would largely be attenuated at low LDL-C levels. Results from the Copenhagen City Heart
In a collaborative effort between the groups of Vascular Medicine and Medical Biochemistry of the Academic Medical Center (Prof. Erik Stroes, Prof. de Winther) a review article has been published in the esteemed Athersclerosis journal (Oct, 2018). In this review, potential epigenetic compounds are studied that could be utilized to prevent or treat atherosclerosis based on
In the first 6–9 months following an acute coronary syndrome (ACS), patients face a disproportionally increased risk of reinfarction. Following an ACS in patients, studies have substantiated that 18F-fluordeoxyglucose (18F-FDG) uptake in bone-marrow and spleen is increased, visualized with positron emission tomography/ computed tomography (PET/CT). This increased uptake coincides with increased inflammatory parameters in plasma
The groups of Prof. Stroes (Amsterdam) and Prof. Nahrendorf (Boston) reviewed recent advances in the connection between hematopoiesis and atherogenesis. Atherogenesis is the result of a complex interplay between lipids and innate immune cells, which are descendants of upstream progenitors residing in hematopoietic organs. The relevance of a neural–hematopoietic axis was recently supported by the demonstration of
The group from Radboud UMC (Prof. N. Riksen, Prof. M. Netea) co-authored a paper published in Cell earlier this year (11 January 2018) in which work from the REPROGRAM project is mentioned. Today, in Western societies, over 80% of deaths are due to non-communicable diseases including those associated with aging and diseases caused or influenced by the consumption of
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.